Procter & Gamble Health Limited (PGHL) Q2 FY27 Financial Results: PAT ₹96 & Revenue ₹356 Cr

Investor Takeaways

• Revenue grew 7% YoY to ₹356 crores in Q1 FY2026
• Net Profit surged 45% YoY to ₹96 crores
• Operational PAT increased 9% YoY excluding one-time gain
• ⚠️ One-time asset sale contributed to PAT growth

Overall Tone: Positive

Key Financial Highlights

What Changed

The filing reveals robust financial performance for Procter & Gamble Health Limited in Q1 FY2026, with both top-line and bottom-line metrics showing significant improvement year-on-year. Revenue increased by 7% to ₹356 crores, indicating healthy demand or pricing power in the VMS (Voltage Management System) segment. Net Profit rose sharply by 45% to ₹96 crores, driven primarily by brand strength and a one-time asset sale. However, when adjusted for this non-recurring gain, operational PAT growth was more modest at 9% YoY, suggesting underlying business momentum remains stable but not accelerating dramatically. The company demonstrated improved profitability, though the disproportionate PAT growth relative to revenue warrants attention regarding sustainability. Compared to peers, PGHL trades at a P/E of 29.98, below Sun Pharma (41.28) and significantly below Divi's Laboratories (72.41) and Torrent Pharma (80.06), potentially reflecting market skepticism on future growth or higher earnings volatility. The absence of ROE and ROCE data limits deeper efficiency assessment, but the strong quarterly results and market positioning in healthcare suggest improving operational execution.

Peer Comparison

PGHL trades at a lower valuation multiple compared to peers, but lacks disclosed profitability ratios, limiting direct efficiency comparison.

Risks & Concerns

• No specific risks identified in the filing beyond reliance on brand performance and potential volatility from one-time gains
• One-time asset sale contributed to PAT growth, which may not be recurring
• OPM and EBITDA margins not disclosed, limiting margin trend analysis

Quarterly Trend

Not applicable — quarterly trend data for multiple periods is not provided in the context. Only Q1 FY2026 figures are available.